Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Daily News

Cardioprotective Flush, Without Reanimation, Safe and Effective in DCD Transplant

Michael O'Riordan

January 28, 2026

News Conference News HFSA 2025

Voice Analysis Picks Up Patients at Risk for HF Hospitalization: COMMUNITY-HF

Yael L. Maxwell

September 29, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Conference News ESC Heart Failure 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

Todd Neale

May 19, 2025

News Daily News

Lower Risk of Mortality for Shock Patients Transferred to Expert Centers

Caitlin E. Cox

March 17, 2025

News Daily News

CVD Hospitalization in Older Adults Higher in US Than in Denmark

Michael O'Riordan

February 07, 2025

News Daily News

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

Todd Neale

September 13, 2023

News Daily News

Hospital at Home Strategy Could Disrupt ‘Low-Value’ Care for Worsening HF

L.A. McKeown

September 07, 2023

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Conference News ESC Heart Failure 2022

Speech-Recognition Tool May Predict Worsening Congestion in HF

Shelley Wood

May 22, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

Todd Neale

January 26, 2022

News Daily News

One in Six HF Patients Delay or Forego Care, Inflating Costs

Shelley Wood

August 12, 2021

News Conference News HRS 2021

Catheter Ablation ‘Good Value’ in CABANA Economic Analysis

Michael O'Riordan

August 04, 2021

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

News Industry News

New Data Confirms Cardiac Dimensions’ Carillon® System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation

February 25, 2020

News Industry News

Reduce Fmr Study Shows Cardiac Dimensions’ Carillon® System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure

September 12, 2019

News Daily News

One in Two Americans Have Cardiovascular Disease: AHA Stats

Michael O'Riordan

February 04, 2019

News Conference News TVT 2017

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Michael O'Riordan

June 20, 2017

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

Advertisement

Cardioprotective Flush, Without Reanimation, Safe and Effective in DCD Transplant

Voice Analysis Picks Up Patients at Risk for HF Hospitalization: COMMUNITY-HF

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

Lower Risk of Mortality for Shock Patients Transferred to Expert Centers

CVD Hospitalization in Older Adults Higher in US Than in Denmark

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

Hospital at Home Strategy Could Disrupt ‘Low-Value’ Care for Worsening HF

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Speech-Recognition Tool May Predict Worsening Congestion in HF

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

One in Six HF Patients Delay or Forego Care, Inflating Costs

Catheter Ablation ‘Good Value’ in CABANA Economic Analysis

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

New Data Confirms Cardiac Dimensions’ Carillon® System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation

Reduce Fmr Study Shows Cardiac Dimensions’ Carillon® System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure

One in Two Americans Have Cardiovascular Disease: AHA Stats

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content